Translational Research Working Group Public Comment Period, 62114-62115 [E6-17699]
Download as PDF
<![CDATA[
62114
Federal Register / Vol. 71, No. 204 / Monday, October 23, 2006 / Notices
Proposed Collection
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Pre-Testing of NCI
Communication Messages
SUMMARY: Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Cancer Institute (NCI), the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on August 14,
2006, page 46486 and allowed 60 days
for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment. The
National Institutes of Health may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
Title: Pretesting of NCI
Communication Messages. Type of
Information Collection Request:
EXTENSION (OMB# 0925–0046, expires
10/31/06). Need and Use of Information
Collection: In order to carry out NCI’s
legislative mandate to educate and
disseminate information about cancer
prevention, detection, diagnosis, and
treatment to a wide variety of audiences
and organizations (e.g, cancer patients,
their families, the general public, health
providers, the media, voluntary groups,
scientific and medical organizations), it
is beneficial for NCI to pretest their
communications strategies, concepts,
and messages while they are under
development. The primary purpose of
this pretesting, or formative evaluation,
is to ensure that the messages,
communication materials, and
information services created by NCI
have the greatest capacity of being
received, understood, and accepted by
their target audiences. By utilizing
appropriate qualitative and quantitative
methodologies, NCI is able to (1)
understand characteristics of the
intended target audience—their
attitudes, beliefs, and behaviors—and
use this information in the development
of effective communication tools and
strategies; (2) produce or refine
messages that have the greatest potential
to influence target audience attitudes
and behavior in a positive manner; and
(3) expend limited program resource
dollars wisely and effectively.
Frequency of Response: On occasion.
Affected Public: Individuals or
households; businesses or other for
profit; not-for-profit institutions; Federal
Government; State, local, or tribal
government. Type of Respondents:
Adult cancer patients; members of the
public; health care professionals;
organizational representatives. The
annual reporting burden is as follows:
Estimated Number of Respondents:
13,780; Estimated Number of Responses
per Respondent: 1; Average Burden
Hours Per Response: .1458; and
Estimated Total Annual Burden Hours
Requested: 2,010. The annualized cost
to respondents is estimated at: $34,155.
There are no capital costs, operating
costs, and/or maintenance costs to
report.
ESTIMATE HOURS OF BURDEN
Type of
respondents
Number of
respondents
Frequency of
response
Average time
per response
Annual hour
burden
13,780
1
.1458
2009.12
Total ..........................................................................................................
mstockstill on PROD1PC76 with NOTICES
Adults 18+ ........................................................................................................
13,780
........................
........................
2009.12
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
VerDate Aug<31>2005
15:50 Oct 20, 2006
Jkt 211001
public burden and associated response
time, should be directed to the Office of
Management and Budget, Office of
Regulatory Affairs, New Executive
Office Building, Room 10235,
Washington, DC 20503, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact Nina
Goodman, Senior Analyst, Operations
Research Office, OESI, NCI, NIH, 6116
Executive Blvd., Suite 400, Rockville,
MD 20892, call non-toll-free number
301–435–7789 or e-mail your request,
including your address to:
goodmann@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Dated: October 16, 2006.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. E6–17708 Filed 10–20–06; 8:45 am]
BILLING CODE 4101–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Translational Research Working Group
Public Comment Period
National Cancer Institute (NCI),
National Institutes of Health (NIH),
Department of Health and Human
Services (HHS).
ACTION: Request for public comment.
AGENCY:
SUMMARY: The Translational Research
Working Group (TRWG), a broad panel
including advocates, researchers from
academia, industry representatives, and
government officials, was established in
early 2005 to evaluate the status of the
E:\FR\FM\23OCN1.SGM
23OCN1
Federal Register / Vol. 71, No. 204 / Monday, October 23, 2006 / Notices
National Cancer Institute’s (NCI)
intramural and extramural investment
in translational research in order to
develop recommendations on ways to
coordinate and optimally integrate
activities. The TRWG is also charged
with developing implementation
strategies that will enable the scientific
community and NCI leadership to
appropriately prioritize its translational
research opportunities.
Recommendations will be made to the
National Cancer Advisory Board in early
2007. To assist in its future planning
efforts, the TRWG is asking interested
parties for feedback on the seventeen
draft initiatives they are proposing. The
TRWG compiled these draft initiatives
from the comments received during the
previous public comment period in
early 2006. These draft initiatives
address the obstacles to a successful
translational research enterprise
identified by the TRWG. By listening to
interested parties and stakeholders from
the wider community, the TRWG hopes
to enhance this exciting and important
activity—charting the future course of
translational progress against cancer.
DATES: Parties interested in submitting
comments on the draft initiatives should
submit them by November 22, 2006.
ADDRESSES: Comments may be
submitted electronically to the TRWG
Web site: https://www.cancer.gov/trwg/.
SUPPLEMENTARY INFORMATION:
mstockstill on PROD1PC76 with NOTICES
Background
The National Cancer Institute is
committed to speeding the development
of new diagnostic tests, cancer
treatments, and other interventions that
benefit people with cancer and people
at risk for cancer. Such development
relies on strong translational research
collaborations between basic and
clinical scientists to generate novel
approaches. Currently, NCI supports a
variety of projects that build this bridge
between basic science and patient care.
Over the past year, the Translational
Research Working Group (TRWG)
reviewed NCI’s current intramural and
extramural translational research
portfolio (within the scope of the TRWG
mission), facilitated broad community
input, invited public comment, and
recommended ways to improve and
integrate efforts. The ultimate goal is to
accelerate progress toward improving
the health of the nation and cancer
patient outcomes.
Request for Comments
To better address the obstacles a
successful translational research
enterprise may face and to ensure the
different viewpoints in the cancer
VerDate Aug<31>2005
15:50 Oct 20, 2006
Jkt 211001
research community are represented,
the TRWG seeks input on the following
challenges and the steps to facing them:
• Insufficient coordination and
integration across NCI results in a
fragmented translational research effort
that risks duplication and may miss
important opportunities.
• Absence of clearly designated
funding and adequate incentives for
researchers threatens the perceived
importance of translational research
within the NCI enterprise.
• Absence of a structured, consistent
review and prioritization process
tailored to the characteristics and goals
of translational research makes it
difficult to direct resources to critical
needs and opportunities.
• Translational research core services
are often duplicative and inconsistently
standardized, with capacity poorly
matched to need.
• Multidisciplinary nature of
translational research and the need to
integrate sequential steps in complex
development pathways warrants
dedicated project management
resources.
• Inadequate collaboration with
industry delays appropriate
developmental hand-offs.
• Extended negotiation on
intellectual property issues delays or
prevent potentially productive
collaborations.
• Inadequate collaboration with
foundations/advocacy groups risks
missing important opportunities for
integration of translational research
efforts and patient outreach.
• Insufficient collaboration and
communication between basic and
clinical scientists and the paucity of
effective training opportunities limits
the supply of experienced translational
researchers.
FOR FURTHER INFORMATION CONTACT:
Ernest Hawk, M.D., M.P.H., Director,
Office of Centers, Training and
Resources, National Cancer Institute,
National Institutes of Health. Or visit
the TRWG Web site at https://
www.cancer.gov/trwg.
Dated: October 17, 2006.
Ernest Hawk,
Director, Office of Centers, Training and
Resources, National Cancer Institute,
National Institutes of Health.
[FR Doc. E6–17699 Filed 10–20–06; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
62115
DEPARTMENT OF HOMELAND
SECURITY
Bureau of Customs and Border
Protection
Bureau of Customs and Border
Protection Trade Symposium 2006:
‘‘The World of Trade—5 Years After
9/11’’
Customs and Border Protection,
Department of Homeland Security.
ACTION: Notice of trade symposium.
AGENCY:
SUMMARY: This document announces
that the Bureau of Customs and Border
Protection (CBP) will convene a major
trade symposium that will feature panel
discussions involving department
personnel, members of the trade
community and other government
agencies on the agency’s role on
international trade security initiatives
and programs. Members of the
international trade and transportation
communities and other interested
parties are encouraged to attend and to
register early.
DATES: Wednesday, December 13, 2006
(opening reception—6 to 8 p.m.);
Thursday, December 14, 2006 (panel
discussions, luncheon and open forum
with senior management—8:30 a.m. to 6
p.m.); Friday, December 15, 2006 (halfday session with panel discussions—8
a.m. to 1 p.m.) will be held.
ADDRESSES: The Trade Symposium will
be held at the Ronald Reagan Building
and International Trade Center, 1300
Pennsylvania Avenue, NW.,
Washington, DC. Upon entry into the
building, a photo identification must be
presented to the security guards.
FOR FURTHER INFORMATION CONTACT: The
Office of Trade Relations at (202) 344–
1440 or at traderelations@dhs.gov. ACS
Client Representatives; CBP Account
Managers; Regulatory Audit Trade
Liaisons; or to obtain the latest
information on the Symposium and to
register on-line, visit the CBP Web site
at https://www.cbp.gov. Requests for
special needs should also be sent to the
Office of Trade Relations at
traderelations@dhs.gov.
The
keynote speaker will be announced at a
later date. The cost is $250.00 per
individual and includes all symposium
activities. Interested parties are
requested to register early, as space is
limited. Registration will open to the
public on or about November 1, 2006.
All registrations must be made on-line
through the CBP Web site (https://
www.cbp.gov) and be confirmed with
payment by credit card only. The JW
SUPPLEMENTARY INFORMATION:
E:\FR\FM\23OCN1.SGM
23OCN1
]]>Agencies
[Federal Register Volume 71, Number 204 (Monday, October 23, 2006)]
[Notices]
[Pages 62114-62115]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-17699]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Translational Research Working Group Public Comment Period
AGENCY: National Cancer Institute (NCI), National Institutes of Health
(NIH), Department of Health and Human Services (HHS).
ACTION: Request for public comment.
-----------------------------------------------------------------------
SUMMARY: The Translational Research Working Group (TRWG), a broad panel
including advocates, researchers from academia, industry
representatives, and government officials, was established in early
2005 to evaluate the status of the
[[Page 62115]]
National Cancer Institute's (NCI) intramural and extramural investment
in translational research in order to develop recommendations on ways
to coordinate and optimally integrate activities. The TRWG is also
charged with developing implementation strategies that will enable the
scientific community and NCI leadership to appropriately prioritize its
translational research opportunities. Recommendations will be made to
the National Cancer Advisory Board in early 2007. To assist in its
future planning efforts, the TRWG is asking interested parties for
feedback on the seventeen draft initiatives they are proposing. The
TRWG compiled these draft initiatives from the comments received during
the previous public comment period in early 2006. These draft
initiatives address the obstacles to a successful translational
research enterprise identified by the TRWG. By listening to interested
parties and stakeholders from the wider community, the TRWG hopes to
enhance this exciting and important activity--charting the future
course of translational progress against cancer.
DATES: Parties interested in submitting comments on the draft
initiatives should submit them by November 22, 2006.
ADDRESSES: Comments may be submitted electronically to the TRWG Web
site: https://www.cancer.gov/trwg/.
SUPPLEMENTARY INFORMATION:
Background
The National Cancer Institute is committed to speeding the
development of new diagnostic tests, cancer treatments, and other
interventions that benefit people with cancer and people at risk for
cancer. Such development relies on strong translational research
collaborations between basic and clinical scientists to generate novel
approaches. Currently, NCI supports a variety of projects that build
this bridge between basic science and patient care.
Over the past year, the Translational Research Working Group (TRWG)
reviewed NCI's current intramural and extramural translational research
portfolio (within the scope of the TRWG mission), facilitated broad
community input, invited public comment, and recommended ways to
improve and integrate efforts. The ultimate goal is to accelerate
progress toward improving the health of the nation and cancer patient
outcomes.
Request for Comments
To better address the obstacles a successful translational research
enterprise may face and to ensure the different viewpoints in the
cancer research community are represented, the TRWG seeks input on the
following challenges and the steps to facing them:
Insufficient coordination and integration across NCI
results in a fragmented translational research effort that risks
duplication and may miss important opportunities.
Absence of clearly designated funding and adequate
incentives for researchers threatens the perceived importance of
translational research within the NCI enterprise.
Absence of a structured, consistent review and
prioritization process tailored to the characteristics and goals of
translational research makes it difficult to direct resources to
critical needs and opportunities.
Translational research core services are often duplicative
and inconsistently standardized, with capacity poorly matched to need.
Multidisciplinary nature of translational research and the
need to integrate sequential steps in complex development pathways
warrants dedicated project management resources.
Inadequate collaboration with industry delays appropriate
developmental hand-offs.
Extended negotiation on intellectual property issues
delays or prevent potentially productive collaborations.
Inadequate collaboration with foundations/advocacy groups
risks missing important opportunities for integration of translational
research efforts and patient outreach.
Insufficient collaboration and communication between basic
and clinical scientists and the paucity of effective training
opportunities limits the supply of experienced translational
researchers.
FOR FURTHER INFORMATION CONTACT: Ernest Hawk, M.D., M.P.H., Director,
Office of Centers, Training and Resources, National Cancer Institute,
National Institutes of Health. Or visit the TRWG Web site at https://
www.cancer.gov/trwg.
Dated: October 17, 2006.
Ernest Hawk,
Director, Office of Centers, Training and Resources, National Cancer
Institute, National Institutes of Health.
[FR Doc. E6-17699 Filed 10-20-06; 8:45 am]
BILLING CODE 4140-01-P
